Published online Jul 27, 2023. doi: 10.4240/wjgs.v15.i7.1388
Peer-review started: February 11, 2023
First decision: March 26, 2023
Revised: April 5, 2023
Accepted: May 6, 2023
Article in press: May 6, 2023
Published online: July 27, 2023
Processing time: 160 Days and 5.3 Hours
As ultrasound-guided percutaneous liver biopsy (PLB) has become a standard and important method in the management of liver disease in our country, a periodical audit of the major complications is needed.
As ultrasound-guided PLB has become a standard and important method in the management of liver disease in our country, a periodical audit on its application and complications is needed to ensure that the complication rate is within the accepted range and to further optimize the procedure. Therefore, we carried out this study to determine the annual incidence of major complications following ultrasound-guided PLB in a Chinese tertiary-care teaching hospital and to identify significant variables associated with an increased risk of major complications.
The aim of this study was to determine the annual incidence of major complications following ultrasound-guided PLB and to identify variables that were significantly associated with an increased risk of major complications.
A total of 1857 consecutive cases of PLB were included in our hospital from January 2021 to December 2021. The major complication rate and all-cause 30-d mortality rate were determined. Multivariate analyses were performed by logistic regression to investigate the risk factors associated with major complications and all-cause 30-d mortality following ultrasound-guided PLB.
In this audit of 1857 liver biopsies, 10 cases (0.53%) of major complications occurred following ultrasound-guided PLB. The overall all-cause mortality rate at 30 d after PLB was 0.27% (5 cases), and 2 cases (0.11%) were attributed to major hemorrhage within 7 d after liver biopsy. Fibrinogen less than 2 g/L [odds ratio (OR): 17.226; 95% confidence interval (CI): 2.647-112.102; P = 0.003], post-biopsy hemoglobin level (OR: 0.963; 95%CI: 0.942-0.985; P = 0.001), obstructive jaundice (OR: 6.698; 95%CI: 1.133-39.596; P = 0.036), application of anticoagulants/antiplatelet medications (OR: 24.078; 95%CI: 1.678-345.495; P = 0.019) and age (OR: 1.096; 95%CI: 1.012-1.187; P = 0.025) were statistically associated with the incidence of major complications after PLB.
In conclusion, the results of this annual audit confirmed that ultrasound-guided PLB can be performed safely, with a major complication rate within the accepted range. Strict patient selection and peri-biopsy laboratory assessment are more important than procedural factors for optimizing the safety outcomes of this procedure.
A large-scale, multicenter and prospective study is warranted to validate the findings of our study, especially the administration of peri-biopsy coagulants/antiplatelet medications and the assessment of the baseline coagulation profile.